Literature DB >> 21464157

Diverging trends in incidence and mortality, and improved survival of non-Hodgkin's lymphoma, in the Netherlands, 1989-2007.

S A M van de Schans1, D E Issa, O Visser, P Nooijen, P C Huijgens, H E Karim-Kos, M L G Janssen-Heijnen, J W W Coebergh.   

Abstract

BACKGROUND: We studied progress in the fight against non-Hodgkin's lymphoma (NHL) in the Netherlands by describing the changes in incidence, treatment, relative survival, and mortality during 1989-2007. PATIENTS AND METHODS: We included all adult patients with NHL [i.e. all mature B-, T-, and natural killer (NK) cell neoplasms, with the exception of plasma cell neoplasms], newly diagnosed in the period 1989-2007 and recorded in the Netherlands Cancer Registry (n=55 069). Regular mortality data were derived from Statistics Netherlands. Follow-up was completed up to 1 January 2009. Annual percentages of change in incidence, mortality, and relative survival were calculated.
RESULTS: The incidence of indolent B-cell and T- and NK-cell neoplasms rose significantly (estimated annual percentage change=1.2% and 1.3%, respectively); incidence of aggressive B-cell neoplasms remained stable. Mortality due to NHL remained stable between 1989 and 2003, and has decreased since 2003. Five-year relative survival rates rose from 67% to 75%, and from 43% to 52%, respectively, for indolent and aggressive mature B-cell neoplasms, but 5-year survival remained stable at 48% for T- and NK-cell neoplasms.
CONCLUSIONS: In the Netherlands, incidence of indolent mature B-cell and mature T- and NK-cell neoplasms has increased since 1989 but remained stable for aggressive neoplasms. Survival increased for all mature B-cell neoplasms, preceding a declining mortality and increased prevalence of NHL (17 597 on 1 January 2008).

Entities:  

Mesh:

Year:  2011        PMID: 21464157     DOI: 10.1093/annonc/mdr055

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  13 in total

1.  Actual prognosis during follow-up of survivors of B-cell non-Hodgkin lymphoma in the Netherlands.

Authors:  Saskia A M van de Schans; Liza N van Steenbergen; Jan Willem W Coebergh; Maryska L G Janssen-Heijnen; Dick Johan van Spronsen
Journal:  Haematologica       Date:  2013-09-13       Impact factor: 9.941

2.  A high level of fatigue among long-term survivors of non-Hodgkin's lymphoma: results from the longitudinal population-based PROFILES registry in the south of the Netherlands.

Authors:  Simone Oerlemans; Floortje Mols; Djamila E Issa; J H F M Pruijt; Wim G Peters; Marnix Lybeert; Wobbe Zijlstra; Jan Willem W Coebergh; Lonneke V van de Poll-Franse
Journal:  Haematologica       Date:  2012-08-28       Impact factor: 9.941

3.  Cause-specific mortality among Medicare beneficiaries with newly diagnosed non-Hodgkin lymphoma subtypes.

Authors:  Laura L Hester; Steven I Park; William A Wood; Til Stürmer; M Alan Brookhart; Jennifer L Lund
Journal:  Cancer       Date:  2018-12-11       Impact factor: 6.860

4.  The epidemic of non-Hodgkin lymphoma in the United States: disentangling the effect of HIV, 1992-2009.

Authors:  Meredith S Shiels; Eric A Engels; Martha S Linet; Christina A Clarke; Jianmin Li; H Irene Hall; Patricia Hartge; Lindsay M Morton
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-04-17       Impact factor: 4.254

5.  Assessing the impact of cancer among Dutch non-Hodgkin lymphoma survivors compared with their American counterparts: a cross-national study.

Authors:  Simone Oerlemans; Sophia K Smith; Catherine M Crespi; Sheryl Zimmerman; Lonneke V van de Poll-Franse; Patricia A Ganz
Journal:  Psychooncology       Date:  2012-07-26       Impact factor: 3.894

6.  The course of anxiety and depression for patients with Hodgkin's lymphoma or diffuse large B cell lymphoma: a longitudinal study of the PROFILES registry.

Authors:  Simone Oerlemans; Floortje Mols; Marten R Nijziel; Wobbe P Zijlstra; Jan Willem W Coebergh; Lonneke V van de Poll-Franse
Journal:  J Cancer Surviv       Date:  2014-05-13       Impact factor: 4.442

7.  Socioeconomic position, treatment, and survival of non-Hodgkin lymphoma in Denmark--a nationwide study.

Authors:  B L Frederiksen; S O Dalton; M Osler; M Steding-Jessen; P de Nully Brown
Journal:  Br J Cancer       Date:  2012-02-07       Impact factor: 7.640

8.  Long-term time trends in incidence, survival and mortality of lymphomas by subtype among adults in Manitoba, Canada: a population-based study using cancer registry data.

Authors:  Xibiao Ye; Salaheddin Mahmud; Pamela Skrabek; Lisa Lix; James B Johnston
Journal:  BMJ Open       Date:  2017-07-17       Impact factor: 2.692

9.  International development of four EORTC disease-specific quality of life questionnaires for patients with Hodgkin lymphoma, high- and low-grade non-Hodgkin lymphoma and chronic lymphocytic leukaemia.

Authors:  Lonneke van de Poll-Franse; Simone Oerlemans; Anne Bredart; Charalampia Kyriakou; Monika Sztankay; Stephan Pallua; Laurien Daniëls; Carien L Creutzberg; Kim Cocks; Sandra Malak; Giovanni Caocci; Stefano Molica; Weichu Chie; Fabio Efficace
Journal:  Qual Life Res       Date:  2017-11-10       Impact factor: 4.147

10.  More frequent use of health care services among distressed compared with nondistressed survivors of lymphoma and chronic lymphocytic leukemia: Results from the population-based PROFILES registry.

Authors:  Lindy P J Arts; Simone Oerlemans; Lidwine Tick; Ad Koster; Henk T J Roerdink; Lonneke V van de Poll-Franse
Journal:  Cancer       Date:  2018-04-26       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.